Clinical Trial Update: A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma [Phase 3]

View source ↗

Summary

A Phase III trial is evaluating first-line therapy with anlotinib in combination with benmelstobart for advanced esophageal squamous cell carcinoma; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• Benmelstobart

Snippet

Sponsor: The First Affiliated Hospital of Zhengzhou University | Conditions: Advanced Esophageal Squamous Cell Carcinoma | Phase 3 | Status: NOT_YET_RECRUITING